Kaken Pharmaceutical (TYO:4521) revised its consolidated earnings forecast for the fiscal year ending March 31, raising net sales outlook to 94 billion yen due to an upfront payment from a licensing deal for its STAT6 inhibitor.
Net profit was slightly adjusted downward to 14 billion yen, reflecting expenses from a recent dermatology licensing agreement and the acquisition of Aadi Subsidiaries, according to its Tuesday bourse filing.
The revision follows deals disclosed in December 2024 and March 2025, including a collaboration with Alumis for ESK-001 in Japan and the completion of Aadi's acquisition.
Despite the adjustments, Kaken's projected earnings still show significant growth compared with the previous fiscal year, with net sales up 30.5% and operating profit more than doubling.
Shares of the company dropped over 5% in morning trade Wednesday.
Price (JPY): $4236.00, Change: $-230, Percent Change: -5.13%
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。